Analyser for automatic determination of hemostatic profile
SUBSTANCE: analyser has a revolving cuvette with a sample in which there is a control ferromagnetic ball, a magnet which can interact with said ball, a coagulation sensor which transmits signals from the ball and having a Hall sensor and a magnet, a signal processing device in form of a power supply unit, a Hall sensor, a microprocessor and a display device included in a common measuring circuit. The analyser is multi-channelled by fitting at least one additional revolving cuvette to form several channels. All cuvettes lie in a temperature-controlled unit included in the common measuring circuit. The longitudinal axis of each cuvette is inclined at an acute angle to the vertical. In the coagulation sensor, the magnet lies opposite the Hall sensor on the opposite side of the cuvette. The magnet is in form of a flat cylinder mounted with possibility of displacement along the cuvette. The analyser is also fitted with a unit for controlling rotation of the cuvettes and, included in the common measuring a circuit, a measurement parameter adjustment unit having rewritable read-only memory, and a timer configured to automatically switch on when a reactant is fed into the cuvette.
EFFECT: use of the invention increases reliability and broadens functional capabilities of the analyser owing to use of a multichannel measuring circuit, and simplifies the measuring procedure by automating the process.
4 cl, 2 dwg
The invention relates to medical devices, and in particular to structures analyzers hemostasis (coagulometer) and allows to improve the reliability of recording the time of coagulation in the analysis of the blood coagulation system, in particular when determining the basic tests of coagulation based on the registration process fibrinopeptide. Due to the multi-channel significantly increases the performance.
Known ball coagulometer in German patent DE 3523906, CL G01N 11/10, publ. 04.07.1955. Coagulometer contains a rotating cuvette with the sample, which is a controlling ferromagnetic ball sensor that transmits signals from the ball, and device processing of this signal. The ball is attracted and fixed by the magnet located on the side of the cuvette. The coagulation of the ball is captured breakdown is rotationally driven, resulting in a magnetic sensor, located between the ball and the magnet generates a signal processed by the signal processing unit.
The disadvantages of this solution should include low reliability due to low noise immunity due to the fact that:
distance from the ball to the magnet is adjusted so that the force of gravity had set value. As the sensor is mechanically connected with the magnet, and signals the sensor decreases sharply with increasing distance from the sensor to the ball, at large distances, magnet ball, the sensor signal may be very weak, which reduces the accuracy and objectivity of clinical diagnostic tests.
- this device is usually surrounded by other devices and elements that generate magnetic fields of low frequency and large ferromagnetic masses affecting the magnetic sensor. Temperature changes also affect its sensitivity, and this inevitably affects the accuracy of diagnosis (all measurement of blood parameters should be carried out strictly at 37°C). At other temperature proteins are inadequate, therefore, the specified temperature shall be maintained with appropriate technical solutions.
The closest functionality to the proposed analyzer is coagulometer ball containing a rotating cuvette with the sample, which is a controlling ferromagnetic ball, the sensor bulb and the signal processing unit, characterized in that the sensor bulb contains located at the minimum from the cell distance stationary Hall sensor and having a longitudinal movement regulating the force of gravity ball magnet, and a circuit for signal processing includes sequentially located the source of current, a Hall sensor, a voltage amplifier, the filter h is some frequency, filter low frequency, the comparator, the microprocessor, the device starts and the display device, with the device launching connected with the microprocessor and power source. (Patent RU 2133955, CL G01N 11/10, publ. 27.07.1999). This solution is taken as the nearest equivalent.
The disadvantage of this solution is:
- the location in the immediate vicinity of the magnet and the sensor, which leads to a considerable influence of the field magnet on the sensor. In addition, due to the oblong (elongated) shape of the magnet is formed a field that "covers" all the basic elements: the ball, the sensor and the magnet. To address this impact similar used extremely complex circuit and anti-jamming;
- the absence of a system for pre-heating (temperature) to the desired temperature (about 37°C) will not allow the device to function normally, as fibrin threads exactly when this temperature is capable of capturing the ball;
- limited functionality due to odnogolosy, i.e. the impossibility of the simultaneous study of several samples, as well as the lack of output on the external device (computer, printing device) and the possibility of using automatic pipedoctor;
- no additional stabilization system the position of the ball in a ditch for the region is Genia calibration channels and improve the noise immunity will inevitably reduce the reliability of the device.
The technical problem to be solved using the claimed device is increased reliability and enhanced functionality through the creation of multi-channel Electromechanical coagulopathies analyzer with advanced quality and quantity measurements, automation, maximum simplification and ease of use to staff, opportunities to adjust and introduction of new methods of measurement.
The technical result, that is, the invention lies in the realization of multichannel measurement scheme, simplifying the measurement procedure for automating the process, reducing subjective factors measurements, as well as improving the reliability and accuracy of measurements of appropriate technical solutions.
This technical result is achieved due to the fact that the multichannel analyzer for the automatic determination of hemostasis contains a rotating cuvette with the sample, which is a controlling ferromagnetic ball is located with the opportunity to interact with the magnet, the sensor coagulation, transmitting signals from the bulb and including a Hall sensor and a magnet, the signal processing unit in the form included in the total measuring circuit power supply, Hall sensor, high performance embedded the quarrel and display unit, moreover, the multichannel analyzer is built through supply of at least one additional rotating cuvette with the formation of multiple channels, all of the cell are controlled unit included in the measuring circuit, the longitudinal axis of each cell is inclined at an acute angle to the vertical, and the sensor coagulation magnet is opposite to the Hall sensor on the opposite side of the cuvette, and the magnet is made in the form of a flat cylinder mounted for movement along the cell, while the analyzer is equipped with a control unit of rotation of the cuvettes, and is included in the measuring circuit block correction measurement parameters containing writable persistent storage device, and the timer is configured to automatically turn on when adding reagent in the cuvette.
thermostating unit contains devices of light and sound display temperature control.
The analyzer can be equipped with devices for interfacing with external devices - automatic pipestone, a print device and a keyboard.
The analyzer can also be performed with interface connection to a host computer.
The inventive device is illustrated by drawings,
where 1 is a structural block diagram of the device
Figure 2 - General view of the measuring channel of the cuvette and the sensor.
Multi-channel semi-automatic analyzer contains the unit cuvette 1 with samples. Figure 1 shows a variant of the device with four measuring cells, each of which is control of ferromagnetic ball 2 held by the permanent magnet 3 and is associated with the magnetic field sensor (Hall sensor) 4.
The cell with the help of the motor and the control circuit 5 are rotated at a constant speed. The longitudinal axis of each of the cell 1 is inclined at an acute angle to the vertical for operator comfort and improved ergonomics of the analyzer.
In the sensor coagulation magnet 3 is located opposite to the Hall sensor 4 on the opposite side of the cell 1, which increases the stability of the system and eliminates the chance of false positives.
The magnet 3 is made in the form of a flat cylinder mounted for movement along the cell and having axial symmetry of the magnetic field, which simplifies and makes more reliable the site settings of the measuring channels.
Maintaining a constant temperature in the measured cells and cells of the sample preparation is provided by thermostat 6, with length 7 and the audio 8 zone temperature control.
Select the cell in which the measurement is manual 9. Each cell has its own the public display of his condition 10.
The signals from the sensors are received in the controller 11, where for certain programs is the processing of the results. The measurement results are displayed on the display 12.
The management process is carried out using the built-in keyboard 13.
The presence of block correction measurement parameters 14 containing writable persistent storage device, permits (if necessary) to introduce new or modify existing measurement techniques.
Built-in clock 15 maintain medical standards of accountability, in which you want to specify the exact time of the measurement, and also perform the timer function.
The presence of industry-standard interface 16 with galvanic separation 17 allows you to connect external devices (computer, printer).
Automatic pipestone connect using sockets 18. Connect the keyboard is also implemented through the slot 19. The device is powered with built-in power supply unit 20.
The device is a microprocessor-based device to determine a baseline koagulogicheskie tests based on the reception time of the formation of a clot after incubation of the sample with reagents, activating and carrying out the coagulation process up to the formation of a clot.
the Device is a semi-automated system for measuring the time of formation of a clot (mechanical method), used to determine prothrombinase time (PT) sec, prothrombinase time for Quick, %, prothrombinase relations (ON), international normalized ratio (MPE), activated partial thromboplastin time (APTT), sec, thrombosed time, in seconds, fibrinogen according to Klaus, the activity of coagulation factors II, V, VII, VII, IX, X, XI.
The proposed analyzer can be measured by any test, based on the determination of the time of formation of the fibrin clot. For any test is determined only coagulation time. The calculation is performed only if the device is an appropriate methodology. The measurement result can be both quantitative and qualitative.
When using the appropriate reagents as samples you can use plasma or whole blood. Coagulometer applies to "open" systems, i.e. can work with both domestic and imported reagents.
Add samples and reagents is performed manually. Automatically includes the time of the formation of a clot.
The analyzer is a device power failure and is designed to perform the tests required in the inpatient and outpatient environment: in clinical diagnostic laboratories, quality control departments, blood banks, and with utilityowned productions for fractionation of donor blood plasma and other institutions of the blood Service, as well as in research institutes.
The functioning of the inventive device is as follows.
The analyzer uses a special cuvette 1 with ferromagnetic steel (stainless steel) ball 2 (Figure 2). The sample is added into a cuvette and after a suitable time warming up in a special cell of thermostat is transferred to the measuring channel of the analyzer, which rotates slowly (50 rpm) around its longitudinal axis.
Adding the appropriate reagent using pipemaster 18 is automatically activated the timer 15. The device has a connection of two pipedoctor - one for the start of incubation (warm-up) with the corresponding start the timer incubation, the second to start the measurement.
In the unit cell 1 are in the rotation, so that the ball 2 is not spinning randomly in the cell before adding the analyzed samples and reagents, it is by tilting the cell at an acute angle to the vertical and hold the magnet 3 is always lower point that allows easier and more accurate to adjust the system, when this ball performs the function of a mixer. Shifting the ball only under the influence of the emerging strands of fibrin (zagustevanii blood or blood plasma), resulting in displacement of the ball and commit time to this point by the device.
In the process of coagul the logical reaction is the formation of filaments of fibrin, that should stop the ball, which initiates the signal from the sensor coagulation e-stop timer. With the help of thermostat 6 provide the desired temperature in the working cells and in cells for pre-heating the samples.
External keyboard 19 provides adjustment if necessary, the existing methods of measurement (in the "care" parameter) or the introduction of new techniques, for this purpose, the device has a writable persistent storage device.
The pulse from the Hall sensor 4 is fed to a controller which stops the countdown and transmits the value to the display 12 and a printing device connected via the RS232 interface 16. The analyzer provides the ability to store previous measurements.
In comparison with the known analogues of the proposed device is advanced adjustments and the introduction of new measuring techniques, a new set of essential features to ensure declare the above technical result of the measurement, automatic calibration of measurement channels before beginning work on reference reagents (standards), which is implemented by means of software.
This, in turn, increases the objectivity and efficiency measurement, empowerment, reduction of time and the measurements when running tests necessary inpatient and outpatient conditions: in clinical diagnostic laboratories, quality control departments, blood banks and specialized production for fractionation of donor plasma and other institutions of the blood Service, as well as in research institutes.
The use of the analyzer allows to considerably simplify the procedure and process reliability mode register the coagulation time in the analysis of the blood coagulation system in accordance with the nomenclature of tests for coagulation, installed and accepted standards of treatment.
The advantages of the described parser included extending the functionality by including in the measurement circuit of thermostat 6, the interface 16 (allows you to connect a portable printing device), data calibration and measurement data in the computer), EPROM 14 (writable persistent storage device) and a controller 11 corrects if necessary, the so-called "care" parameter during operation of the device, as well as introduce additional measurement techniques, if such a need arises, which significantly extends the capabilities of the device.
In addition, when connecting a computer provided is a current archive data (storing the results of previous measurements).
Implemented as a light and sound display temperature control and measurement, because thermostating unit contains devices light 7 and the audio 8 zone temperature control. The presence of two slots for automatic pipedoctor 18 allows their use automatically (when making use of their working in cuvette reagent) to start the measurement process and incubation (implemented programmatically). At the same time saved and manual mode, allowing you to make samples and reagents manually using the normal budget pipedoctor.
The device is easy to use. When it is used to simplify and automate the work of the laboratory.
Multichannel capability. The measurements are carried out simultaneously in several channels. In addition, the device has cooled channels 6 for preheating subsequent samples. Feeds themselves are absolutely identical, but the process of their composition and implementation of schemes (primarily in relation to suppress interference in the interference part) exclude the possibility of failures. The developed device has passed technical and medical tests. Currently training coagulopathies analyzer for serial production.
1. Analyzer for automatic measurement of hemostasis containing urasawa the Xia cuvette with sample for control of ferromagnetic ball is located with the opportunity to interact with the magnet, the sensor coagulation, transmitting signals from the bulb and including a Hall sensor and a magnet, the signal processing unit in the form included in the total measuring circuit power supply, Hall sensor, microprocessor and display unit, characterized in that it is made multichannel due to supply at least one additional rotating cuvette with the formation of multiple channels, all of the cell are controlled unit included in the measuring circuit, the longitudinal axis of each cell is inclined at an acute angle to the vertical, and the sensor coagulation magnet is opposite to the Hall sensor on the opposite side of the cuvette, and the magnet is made in the form of a flat cylinder mounted for movement along the cell, while the analyzer is equipped with a control unit of rotation of the cuvettes, and is included in the measuring circuit block correction measurement parameters containing writable persistent storage device, and the timer is configured to automatically turn on when adding reagent in the cuvette.
2. The analyzer for the automatic determination of hemostasis according to claim 1, characterized in that h is of thermostating unit contains devices of light and sound display temperature control.
3. The analyzer for the automatic determination of hemostasis according to claim 1, characterized in that it is equipped with devices for interfacing with external devices - automatic pipestone, a print device and a keyboard.
4. The analyzer for the automatic determination of hemostasis according to claim 1, characterized in that it is made with interface connection to a host computer.
SUBSTANCE: blood plasma is examined in 4 minutes after the beginning of spontaneous red blood cell aggregation for free red blood cell count and cell count in aggregates. A percentage of non-aggregated red blood cells (PNA RBC) by formula PNA RBC=FRBSC×100/(TRBCA+FRBSC) wherein FRBSC is the free red blood cell count, TRBCA are total red blood cells in aggregates. If the PNA RBC is 56 to 30%, I degree of severity is stated, 30% to 4% - II degree of severity, less than 4% - III degree of severity.
EFFECT: use of the invention enables objectifying and increasing precision of evaluation of red blood cell aggregation, evaluating an intensity of patient's microcirculation disorders in a relatively short time, and thereby ensuring well-timed adequate complex of therapeutic measures or corrected therapy.
SUBSTANCE: quantity of fibrin-monomers, dissolved in 0.5 N sodium hydroxide, is determined spectrophotometrically with application of ethanol test. Claimed method of quantitative determination of fibrin-monomers in blood makes it possible to reveal pathological process in organism with 95% reliability.
EFFECT: increase of determination accuracy.
2 tbl, 4 ex
SUBSTANCE: thrombosis monitor comprises: a thrombosis chamber, at least in a part of which there is a thrombogenic material; an inlet tube connected to the thrombosis chamber through which blood flows into the thrombosis chamber; a blood supply container connected to the inlet tube; a feed pump for the container; a pressure sensor for measuring pressure applied to the container. A method of thrombosis monitoring consists in the fact that after introduction of an anticoagulant, blood is supplied from the container to the thrombosis chamber by pressing on a fluid placed on a blood layer and having density less than that of the blood layer; it is combined with anticoagulation blood processing or blood coagulation stimulation, and measurement of pressure applied to the container; the thrombogenic material is placed at least in a part of the thrombosis chamber.
EFFECT: group of inventions provides overall assessment of blood coagulation and platelet-cell thrombosis in a medium equivalent to blood flow for evaluation of efficacy of an antithrombotic drug.
11 cl, 15 dwg, 23 ex
SUBSTANCE: for determination of functional state of hemostasis system record of blood coagulation process is performed, current amplitude of blood resistance in first time moment is registered and second resistance of blood at multiple time moment from initial time value is measured. Two resistances and time moments are used to determine maximum blood resistance and time constant, by which blood resistance at the beginning and end of coagulation process is calculated. Obtained parameters are used to determine indices of beginning and end of blood coagulation process. Obtained indices are compared with of the same name indices of blood coagulation process in norm and in case of differently directed deviations disturbances of functional state of hemostasis system are diagnosed.
EFFECT: invention makes it possible to increase measurement accuracy and reduce examination time.
1 tbl, 4 dwg
SUBSTANCE: method is based on a method of observing turbidimetric fibrin clot formation with optical transmission of an incubation medium recorded by ultraviolet radiation band 230 to 320 nm by means of UV-spectrophotometre as a fibrin-polymer detector.
EFFECT: invention enables higher accuracy and sensitivity of the method.
4 ex, 4 dwg
SUBSTANCE: for thrombin production measurement, a layer of said sample contacts with a fluorogenic substratum of thrombin where the thickness of said layer is 0.05 to 5 mm, while the surface area is 10 to 500 mm2. Further, the thrombin production environment in said sample is provided. It is followed by measuring the fluorescence emitted from the layer surface by a fluorescent group released by the fluorescent substratum as a result of an enzymatic action of produced thrombin on said fluorogenic substratum. Besides, the invention ensures a kit for measuring the thrombin activity in the sample.
EFFECT: higher measuring accuracy.
29 cl, 12 dwg, 5 ex
SUBSTANCE: blood is examined. A hematocrit level (H), erythrocyte count (E), thrombocyte count (T) are determined. Said parametres are evaluated. In the event if they keep within the determined limits for the patients with acute coronary syndrome (ACS), then adenosine phosphate induced (ADP-induced) clotting time test samples are prepared. Citrated blood sample 0.4 ml is prepared of whole blood and divided on two samples 0.2 ml. Each of these samples is introduced in a measuring cell, recalcified at temperature 37°C for 2 minutes. Then a magnetic ball mixer is placed in each cell. The measurement is activated, and in three seconds the ADP solution 0.1 ml is introduced. After a clotting reaction, a process time duration is recorded separately for each sample. An arithmetical mean of the derived values is calculated (A). The derived values of each of said parameters are scored. Total score Σ=A+H+E+P shows the risk of recurrent thrombotic events. If Σ=4 points, the low risk is observed; the value Σ=5-6 points shows the medium risk, while Σ=7-10 points - the high risk.
EFFECT: method provides more objective risk evaluation of recurrent thrombotic events in the patients with ACS with its simplicity and low cost.
1 ex, 1 tbl
SUBSTANCE: blood sample is placed in capillary, in whose walls installed are electrodes connected to frequency generator and registering unit, blood electric conductivity is measured at the moment of passing through it of alternating current with frequency 200 Hz, electric coagulogram is registered and used to determine chronometric and amplitude characteristics: A - amplitude of functional curve decline, mV; N - time of functional curve decline to minimal value in minutes. If value of A/T index decreases or increases with respect to normal, conclusion about hemostatic disorders is made. If value of A/T index equals 3-5 - hemostasis state is evaluated as normal, if A/T value is lower than 3, hypocoagulation is determined, and if A/T value is higher than 5 - hypercoagulation.
EFFECT: application of the method makes it possible to obtain data about hemostasis system state in real time mode, without injuring form blood elements in investigated microvolumes of blood, thus making it possible to increase accuracy, self-descriptiveness and efficiency of hemostasis state evaluation and to carry out correction of performed therapy without delay.
4 dwg, 3 ex
SUBSTANCE: in patients with IHD before therapy with acetylsalisylic acid (ASA) ADP-induced and ASA-dependent platelet aggregation are examined and by their difference value of coefficient of aggregation inhibition (CAI) is calculated. CAI value <24% testifies to resistance to ASA, if CAI ≥24% - about sensitivity to ASA.
EFFECT: method ensures high prediction accuracy and makes it possible to prevent development of undesirable coronary events in IHD patients.
1 tbl, 4 ex, 4 dwg
SUBSTANCE: invention refers to medicine, namely to haematology, and orthopaedics. The intravascular thrombocyte activity correction in children with scoliosis requires the prescription for at least 6 months of a therapeutic complex which involves daily therapeutic physical training, two courses of massage and daily swimming for at least 20 minutes a day.
EFFECT: method allows to normalise intravascular thrombocyte activity in children aged 8-12 with scoliosis, to improve tissue microcirculation considerably, to optimise growth and development of skeleton and internals.
SUBSTANCE: method of therapy of a cardiovascular pathology involves laboratory assay of a number of blood circulating membrane microparticles, with additionally prescribed Preductal MB 0.35 1 tablet × twice a day with underlying basic therapy or as independent therapy: the number of membrane microparticles exceeding 40 in 4 cm2 of a slide - for 1 month that is followed by another blood sampling for the content of microparticles and making a decision on the further therapeutic approach involving Preductal; the normalised values - the therapeutic course is continued for 3 months; the preserved high values of the content of the membrane microparticles - the therapeutic course is continued for 6 months under laboratory control of the content of microparticles.
EFFECT: reduced number of blood circulating membrane microparticles creates a protective effect on vascular endothelium, prevents the development or the progression of endothelial dysfunction, reduces a risk of the onset and the progression of the cardiovascular diseases.
4 ex, 3 dwg
SUBSTANCE: invention can be used for prediction of risk of development of arterial hypertension in patients with primary osteoarthrosis (POA). Invention is based on determination of duration in years (DKS) and intensity (VASH) of pain syndrome, calculation of number of desquamated endotheliocytes in blood (DEC) with further calculation of coefficient by formula K= DKS*DEC*VASH)/100. If coefficient value is more than 1, conclusion about high risk of arterial hypertension development is made. If coefficient value is lower than 1, probability of AH development is relatively low.
EFFECT: application of the method makes it possible to predict development of AH in said category of patients with high reliability and take adequate prophylactic and therapeutic measures in due time.
2 tbl, 3 ex
SUBSTANCE: total quantitative content of glucose and lactic acid (lactate) in whole blood from two different parts of peripheral venous system of corpse: femoral vein and sinuses of dura mater is determined. If difference of total value in terms of glucose is higher than 5.0 mmol/l, acute cerebral circulation dysfunction is diagnosed.
EFFECT: application of the method makes it possible to increase accuracy of diagnostics during long postmortal period.
SUBSTANCE: in pregnant woman in the first trimester of pregnancy leukocyte index of intoxication is calculated and if its value is higher than 3.0, formation of congenital defect of fetus development is predicted.
EFFECT: simplified prediction of formation of congenital defects of fetus development in pregnant woman in the first trimester of pregnancy with high reliability of obtained results, ensuring justified administration of timely treatment aimed at correction of pathological condition.
SUBSTANCE: peripheral blood is analysed for a percentage of CD62L-CD27- lymphocytes as related to total CD4+ lymphocytes by peripheral blood cell treatment with mixed monoclonal antibodies specific to CD4, CD62L, CD27 markers followed by cell analysis by flow cytometry technique. The analysis is conducted in the beginning of and during treatment. If observing the decreased original percentage of CD62L-CD27 lymphocytes during tuberculosis treatment, terminated (reduced) destructive processes in pulmonary tissue, positive dynamics and clinical effectiveness are stated. The absence of the varying percentage of CD62L-CD27- lymphocytes during treatment with underlying high value testifies to the absence of positive dynamics, continuing pulmonary destruction and a low response to treatment. The increasing percentage of CD62L-CD27- lymphocytes is an indicator of progressing tuberculosis, rising destructive processes in pulmonary tissue and the absence of clinical effectiveness.
EFFECT: use of the method ensures monitoring of tuberculosis treatment, objective evaluation of clinical effectiveness and dynamics of pathological changes in pulmonary tissue.
SUBSTANCE: blood is examined for total protein, albumin, ALT, ACT, urea, bilirubin, creatinine, urine passage, proteinuria, natremia; there are determined gastrointestinal motor evacuation activity, absorption activity, leucocytosis, leukocytic intoxication index; there are evaluated haematological intoxication index, prothrombin index, activated partial thromboplastin time, blood thrombocyte and fibrinogen; each value is scored. An intoxication severity is evaluated; the derived points are summed. If total score is 5 to 17, enteric sorption and combined infusion detoxication are applied; 18 to 36 points - enteric sorption and enteric probe lavage, combined infusion detoxication; 37 points and more - enteric sorption and lavage, combined infusion detoxication and combined extracorporeal detoxication.
EFFECT: use of the method provides more accurate choosing of detoxication approach to acute surgical abdominal pathology.
SUBSTANCE: invention describes a method for evaluating clinical effectiveness in ulcerative colitis that involves analysing pre-therapeutic and therapeutic blood serum samples that is combined with microscopy of two blood serum samples which are dropped on a slide surface; one of them is dried to produce a fascia, while the other one is covered with a cover glass and dehydrated at temperature 24-25°C; the therapy is considered to be effective if observing partially oriented radial cracks in the fascia and parallel lines in the textures of the second sample as shown by the repeated analysis following in 7 days after the beginning of treatment.
EFFECT: instant and reliable evaluation of clinical effectiveness, change of a group of preparations and assessment of their action on an inflammatory process in the colon or adequate proposals for surgical management, reduced risk of severe complications accompanying the therapy, the method does not require special equipment; it is highly economical, accessible by laboratories of healthcare facilities of any capacity.
2 ex, 8 dwg
SUBSTANCE: child's peripheral blood is examined to evaluate the percentage of lymphocytes and the concentration of immunoglobulin M by turbidimetric method in g/l. If the concentration of immunoglobulin M is higher than 1.125 g/l, while the percentage of lymphocytes is higher than 47% (oppositely directed deviances), then a child is referred to a risk group with decreased body resistance to acute respiratory diseases.
EFFECT: use of the method allows high-accuracy prediction of the risk of decreased body resistance to acute respiratory diseases in children between the ages of 3 to 7 in a relatively short time.
1 dwg, 3 ex
SUBSTANCE: reagent for thrombocyte measurement containing Nile blue hydrosulphate as a reagent for thrombocyte staining. A reagents kit for thrombocyte measurement containing Nile blue hydrosulphate as a first reagent, and a buffer solution as a second reagent. A method for thrombocyte measurement wherein Nile blue hydrosulphate is used as the first reagent, and the buffer solution - as the second reagent. A reagent for thrombocyte measurement containing Nile blue and an acid as a staining agent for thrombocyte staining. The reagents kit for thrombocyte measurement containing Nile blue as the first reagent, and a buffer substance as the second reagent. The method for thrombocyte measurement wherein Nile blue and the acid are used as the first reagent, and the buffer substance - as the second reagent.
EFFECT: reagents described above provides higher accuracy of thrombocyte evaluation.
13 cl, 15 dwg, 10 tbl, 48 ex
SUBSTANCE: what is offered is a preoperative diagnostic technique for cerebral glioblastoma. It involves computed tomography and magnetic resonant tomography. Peripheral venous blood is used to produce INF-alpha induced dendritic cells and examined for their cytotoxic activity. If the activity value is lower than 12%, glioblastoma is diagnosed.
EFFECT: invention provides non-invasive preoperative diagnosis of glioblastoma; the diagnostic technique enables estimating the adequacy of such adjuvant routines, as combined immunotherapy and anti-angiogenesis therapy.
FIELD: machine building.
SUBSTANCE: rotational viscometer consists of drive with rotary cylinder secured on its shaft and of coaxial to rotary cylinder input cylinder connected to flexible element. Also, viscometer consists of sensor of angle of rotation of the input cylinder. The flexible element is equipped with rotary and fixed disks. The input cylinder corresponds to a cartridge and is coaxially secured on the rotary disk of the flexible element. The rotary disk is connected with the fixed disk of the flexible element by means of "П"-shaped flat springs uniformly arranged around the shaft. "П"-shaped flat springs are secured radially around periphery of the disks equipped with axial orifices receiving the shaft of the drive. Additionally, the sensor of rotation angle of the input cylinder is made on base of resistive-strain gauges glued on surface of one of the "П"-shaped flat springs.
EFFECT: simplified design, reduced errors at viscosity measurement.
2 cl, 1 dwg